Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is levodopa toxic?

Thomas Müller1, Harald Hefter, Roland Hueber

  • 1Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany. thomas.mueller@ruhr-uni-bochum.de

Journal of Neurology
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agreement between relatives of Parkinson's patients and clinical observer in home diary assessments.

Journal of Parkinson's disease·2026
Same author

Overcoming the diagnostic gap in mild cognitive impairment in Parkinson's disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker.

Frontiers in aging neuroscience·2026
Same author

The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective.

Basic & clinical pharmacology & toxicology·2026
Same author

Non-motor fluctuation patterns in dyskinetic patients with advanced Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Evaluating impulse control disorders in people with Parkinson's disease: agreement and added value of patient and caregiver reports.

Frontiers in neurology·2026
Same journal

Correction: Long-term neurological outcome after hematopoietic stem cell transplant in juvenile Krabbe disease.

Journal of neurology·2026
Same journal

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same journal

Unexpected widespread amyloid PET positivity in a patient with CADASIL.

Journal of neurology·2026
Same journal

Movement disorders in GLUT1 deficiency syndrome: a systematic review of the literature.

Journal of neurology·2026
Same journal

Detailed clinical characteristics of musical hallucinations in 81 patients.

Journal of neurology·2026
Same journal

The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.

Journal of neurology·2026
See all related articles

Levodopa may cause neurotoxicity in Parkinson's disease (PD) patients, particularly through elevated homocysteine. Further research is needed to identify preventive strategies like folic acid supplementation.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Levodopa is a primary treatment for Parkinson's disease (PD).
  • Concerns exist regarding levodopa's potential neurotoxicity.
  • The debate involves preclinical and clinical evidence.

Purpose of the Study:

  • To review and discuss the neurotoxicity debate surrounding levodopa in PD treatment.
  • To consider both preclinical and clinical findings.
  • To evaluate indirect mechanisms of levodopa's effects.

Main Methods:

  • Review of in vitro and animal models of neurodegeneration.
  • Analysis of clinical trials in PD patients using functional imaging.
  • Examination of levodopa-associated homocysteine elevation.

Related Experiment Videos

Main Results:

  • Preclinical models suggest levodopa neurotoxicity; animal models show controversial results.
  • Clinical trials in PD patients lack convincing proof of direct levodopa neurotoxicity.
  • Levodopa-associated homocysteine elevation is an indirect mechanism linked to neurodegeneration progression and atherosclerosis risk.

Conclusions:

  • While direct neurotoxic effects of levodopa are not definitively proven in PD patients, indirect mechanisms like homocysteine elevation are significant.
  • This side effect may contribute to neurodegeneration, peripheral nerve damage, and cardiovascular risks.
  • Future research should investigate long-term toxic effects, peripheral biomarkers, and preventive therapies such as folic acid.